{"entity":{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","aka":[],"tldr":"Kanvas maps which bacteria live in the gut and turns that knowledge into bacterial medicines that help cancer immunotherapy work better and treat its gut side effects.","summary":"Kanvas Biosciences, headquartered at Monmouth Junction, New Jersey, with a West Coast site in South San Francisco, combines high-resolution spatial imaging of microbial communities with strain-resolved culturing and manufacturing to develop live biotherapeutic products. KAN-001 is a defined live biotherapeutic for non-small cell lung cancer intended to enhance response to immune checkpoint inhibitors, with preclinical data and manufacturing consistency presented in November 2025. KAN-004 is a metabolically complete live biotherapeutic for immune checkpoint inhibitor-induced colitis, for which a phase 1 trial was announced in March 2026. The company also offers microbiome research services and announced its own clinical manufacturing capabilities in 2025. In May 2026 Kanvas announced a USD 48 million Series A to bring its microbiome therapeutics to cancer patients; the Gates Foundation separately funds a malnutrition programme.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.kanvasbio.com"},{"label":"News (Series A, KAN-004 phase 1)","url":"https://www.kanvasbio.com/news"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["immunotherapy","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A investors not named on the fetched page; the Business Wire release itself was not fetched. Founding year not sourced."],"hq":"Monmouth Junction, NJ","country":"US","companyType":"biotech","website":"https://www.kanvasbio.com","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2026,"amountUsd":48000000,"source":"https://www.kanvasbio.com/news","note":"Announced via Business Wire, 6 May 2026, as listed on the company news page"}]},"route":"/companies/kanvas-biosciences/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}]}}